Vaxcyte, Inc. (NASDAQ:PCVX) VP Jeff Fairman Sells 10,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVXGet Rating) VP Jeff Fairman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $25.50, for a total transaction of $255,000.00. Following the sale, the vice president now owns 311,227 shares of the company’s stock, valued at $7,936,288.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jeff Fairman also recently made the following trade(s):

  • On Friday, May 20th, Jeff Fairman sold 4,112 shares of Vaxcyte stock. The stock was sold at an average price of $25.50, for a total transaction of $104,856.00.

Vaxcyte Price Performance

NASDAQ PCVX opened at $25.93 on Friday. The company’s fifty day simple moving average is $22.26 and its 200-day simple moving average is $22.75. Vaxcyte, Inc. has a 52 week low of $16.78 and a 52 week high of $27.44.

Vaxcyte (NASDAQ:PCVXGet Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.12). On average, equities research analysts expect that Vaxcyte, Inc. will post -2.7 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new position in shares of Vaxcyte during the first quarter worth about $28,000. Nisa Investment Advisors LLC bought a new stake in Vaxcyte in the fourth quarter valued at about $29,000. Advisor Group Holdings Inc. bought a new stake in Vaxcyte in the fourth quarter valued at about $53,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Vaxcyte in the first quarter valued at about $120,000. Finally, Amalgamated Bank bought a new stake in Vaxcyte in the first quarter valued at about $129,000. 82.18% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

(Get Rating)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.

Featured Stories

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.